Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 12/20 | 0.40 |
| ▸ | HRH1 | P35367 | 12/20 | 0.40 |
| ▸ | ACACB | O00763 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900163 | 1.00 | HRH2 (0.40) | HRH2HRH1ACACBLMNAGPR88 | |
| SCHEMBL2900160 | 1.00 | HRH2 (0.40) | HRH2HRH1ACACBLMNAGPR88 | |
| SCHEMBL2895466 | 0.94 | HRH2 (0.40) | HRH2HRH1ACACBGPR88 | |
| SCHEMBL2895463 | 0.94 | HRH2 (0.40) | HRH2HRH1ACACBGPR88 | |
| SCHEMBL2895468 | 0.94 | HRH2 (0.40) | HRH2HRH1ACACBGPR88 | |
| SCHEMBL2899900 | 0.91 | GPR119 (0.40) | HRH2HRH1ACACBLMNA | |
| SCHEMBL2899896 | 0.91 | GPR119 (0.40) | HRH2HRH1ACACBLMNA | |
| SCHEMBL2899894 | 0.91 | GPR119 (0.40) | HRH2HRH1ACACBLMNA | |
| SCHEMBL8070582 | 0.88 | HRH2 (0.37) | HRH2HRH1ACACBLMNA | |
| SCHEMBL2897008 | 0.87 | HRH2 (0.36) | HRH2HRH1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | HRH2 877/4885HRH1 1577/4885ACACB 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.